Mesfer Alajmi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mesfer Alajmi has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Souvik Roy
Department of Mathematics, University of Texas at Arlington, Arlington, USA
3 shared publications Ibrahem Alshaoosh
University of Tabouk 4 , Tabuk, Tabuk Province, Saudi Arabia
2 shared publications- Ali Alatawi
Department of Mathematics, The University of Texas at Arlington, Arlington, USA
1 shared publication Asma Alghamdi
University of Tabouk 4 , Tabuk, Tabuk Province, Saudi Arabia
1 shared publication- Asma Alghamdi
Department of Mathematics, The University of Texas at Arlington, Arlington, USA
1 shared publication - Bardia Mojra
Department of Computer Science, The University of Texas at Arlington, Arlington, USA
1 shared publication
Latest Publications
- Open Access
- 7 October 2026
- Published by The Royal Society in Royal Society Open Science
- Vol. 13 (10)
A Liouville dynamical modelling and control framework for oesophageal cancer-induced immune response
A Liouville-based framework is developed for optimizing treatment strategies in oesophageal cancer (OC) while accounting for inter-patient heterogeneity. Variability within a patient cohort is represented through uncertain initial cancer and immune cell populations, whose probability distribution is propagated by a Liouville partial differential equation while the underlying individual dynamics remains deterministic. Two optimization problems are considered. First, model parameters are estimated from population-level data using an adjoint-based projected nonlinear conjugate-gradient (NCG) method. Second, optimal time-dependent combinations of chemotherapy and immunotherapy are determined using a sequential quadratic Hamiltonian (SQH) scheme based on Pontryagin’s maximum principle (PMP). The Liouville equation is discretized using a finite-volume method designed to preserve positivity and conservation of the probability density. Numerical experiments with synthetic population data are used to demonstrate the parameter-estimation framework and the ability of the proposed optimal control strategy to determine treatment protocols that effectively modify the population-level cancer–immune response while limiting treatment exposure.
- 7 October 2026
- Published by The Royal Society in Royal Society Open Science
- Vol. 13 (10)
Open AccessA Liouville dynamical modelling and control framework for oesophageal cancer-induced immune response
A Liouville-based framework is developed for optimizing treatment strategies in oesophageal cancer (OC) while accounting for inter-patient heterogeneity. Variability within a patient cohort is represented through uncertain initial cancer and immune cell populations, whose probability distribution is propagated by a Liouville partial differential equation while the underlying individual dynamics remains deterministic. Two optimization problems are considered. First, model parameters are estimated from population-level data using an adjoint-based projected nonlinear conjugate-gradient (NCG) method. Second, optimal time-dependent combinations of chemotherapy and immunotherapy are determined using a sequential quadratic Hamiltonian (SQH) scheme based on Pontryagin’s maximum principle (PMP). The Liouville equation is discretized using a finite-volume method designed to preserve positivity and conservation of the probability density. Numerical experiments with synthetic population data are used to demonstrate the parameter-estimation framework and the ability of the proposed optimal control strategy to determine treatment protocols that effectively modify the population-level cancer–immune response while limiting treatment exposure.
- Open Access
- 31 July 2024
- Published by The Royal Society in Royal Society Open Science
- Vol. 11 (7) , 240347
An evolutionary differential game for regulating the role of monoclonal antibodies in treating signalling pathways in oesophageal cancer
This work presents a new framework for a competitive evolutionary game between monoclonal antibodies and signalling pathways in oesophageal cancer. The framework is based on a novel dynamical model that takes into account the dynamic progression of signalling pathways, resistance mechanisms and monoclonal antibody therapies. This game involves a scenario in which signalling pathways and monoclonal antibodies are the players competing against each other, where monoclonal antibodies use Brentuximab and Pembrolizumab dosages as strategies to counter the evolutionary resistance strategy implemented by the signalling pathways. Their interactions are described by the dynamical model, which serves as the game’s playground. The analysis and computation of two game-theoretic strategies, Stackelberg and Nash equilibria, are conducted within this framework to ascertain the most favourable outcome for the patient. By comparing Stackelberg equilibria with Nash equilibria, numerical experiments show that the Stackelberg equilibria are superior for treating signalling pathways and are critical for the success of monoclonal antibodies in improving oesophageal cancer patient outcomes.
- 31 July 2024
- Published by The Royal Society in Royal Society Open Science
- Vol. 11 (7) , 240347
Open AccessAn evolutionary differential game for regulating the role of monoclonal antibodies in treating signalling pathways in oesophageal cancer
This work presents a new framework for a competitive evolutionary game between monoclonal antibodies and signalling pathways in oesophageal cancer. The framework is based on a novel dynamical model that takes into account the dynamic progression of signalling pathways, resistance mechanisms and monoclonal antibody therapies. This game involves a scenario in which signalling pathways and monoclonal antibodies are the players competing against each other, where monoclonal antibodies use Brentuximab and Pembrolizumab dosages as strategies to counter the evolutionary resistance strategy implemented by the signalling pathways. Their interactions are described by the dynamical model, which serves as the game’s playground. The analysis and computation of two game-theoretic strategies, Stackelberg and Nash equilibria, are conducted within this framework to ascertain the most favourable outcome for the patient. By comparing Stackelberg equilibria with Nash equilibria, numerical experiments show that the Stackelberg equilibria are superior for treating signalling pathways and are critical for the success of monoclonal antibodies in improving oesophageal cancer patient outcomes.
- 5 January 2024
- Published by Springer Nature in Journal of Mathematical Biology
- Vol. 88 (2) , 1-20
A robust optimal control framework for controlling aberrant RTK signaling pathways in esophageal cancer
This study presents a new framework for obtaining personalized optimal treatment strategies targeting aberrant signaling pathways in esophageal cancer, such as the epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) signaling pathways. A new pharmacokinetic model is developed taking into account specific heterogeneities of these signaling mechanisms. The optimal therapies are designed to be obtained using a three step process. First, a finite-dimensional constrained optimization problem is solved to obtain the parameters of the pharmacokinetic model, using discrete patient data measurements. Next, a sensitivity analysis is carried out to determine which of the parameters are sensitive to the evolution of the variants of EGF receptors and VEGF receptors. Finally, a second optimal control problem is solved based on the sensitivity analysis results, using a modified pharmacokinetic model that incorporates two representative drugs Trastuzumab and Bevacizumab, targeting EGF and VEGF, respectively. Numerical results with the combination of the two drugs demonstrate the efficiency of the proposed framework.
- 5 January 2024
- Published by Springer Nature in Journal of Mathematical Biology
- Vol. 88 (2) , 1-20
A robust optimal control framework for controlling aberrant RTK signaling pathways in esophageal cancer
This study presents a new framework for obtaining personalized optimal treatment strategies targeting aberrant signaling pathways in esophageal cancer, such as the epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) signaling pathways. A new pharmacokinetic model is developed taking into account specific heterogeneities of these signaling mechanisms. The optimal therapies are designed to be obtained using a three step process. First, a finite-dimensional constrained optimization problem is solved to obtain the parameters of the pharmacokinetic model, using discrete patient data measurements. Next, a sensitivity analysis is carried out to determine which of the parameters are sensitive to the evolution of the variants of EGF receptors and VEGF receptors. Finally, a second optimal control problem is solved based on the sensitivity analysis results, using a modified pharmacokinetic model that incorporates two representative drugs Trastuzumab and Bevacizumab, targeting EGF and VEGF, respectively. Numerical results with the combination of the two drugs demonstrate the efficiency of the proposed framework.